Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study

RATIONALE: Long-acting injectable (LAI) paliperidone palmitate 1-month formulation (PP1M) has demonstrated acceptable tolerability and favorable clinical outcomes in Western and Asian patients with schizophrenia. Hence, analysis of the outcomes of long-term PP1M treatment specifically in Chinese pat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuropsychiatr Dis Treat
Autors principals: Zhao, Jingping, Li, Lehua, Shi, Jianguo, Li, Yi, Xu, Xiufeng, Li, Keqing, Zhang, Lili, Cai, Shangli, Feng, Yu, Zhuo, Jianmin, Liu, Weihong, Lu, Huafei
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2017
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546821/
https://ncbi.nlm.nih.gov/pubmed/28814873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S131224
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars